CN104039346A - 疫苗疗法 - Google Patents

疫苗疗法 Download PDF

Info

Publication number
CN104039346A
CN104039346A CN201280057432.5A CN201280057432A CN104039346A CN 104039346 A CN104039346 A CN 104039346A CN 201280057432 A CN201280057432 A CN 201280057432A CN 104039346 A CN104039346 A CN 104039346A
Authority
CN
China
Prior art keywords
antigenic peptide
subject
memory
peptide
impairment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201280057432.5A
Other languages
English (en)
Chinese (zh)
Inventor
A·普法伊费尔
A·穆斯
R·马达尼
P·V·贝里琴科
W·C·莫布里
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AC Immune SA
Original Assignee
AC Immune SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AC Immune SA filed Critical AC Immune SA
Priority to CN201910160828.6A priority Critical patent/CN109847058A/zh
Publication of CN104039346A publication Critical patent/CN104039346A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018—Lipids, e.g. in lipopeptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201280057432.5A 2011-09-23 2012-09-21 疫苗疗法 Pending CN104039346A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910160828.6A CN109847058A (zh) 2011-09-23 2012-09-21 疫苗疗法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
USPCT/US2011/052992 2011-09-23
USPCT/US2011/052992 2011-09-23
PCT/US2012/056728 WO2013044147A1 (en) 2011-09-23 2012-09-21 Vaccine therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201910160828.6A Division CN109847058A (zh) 2011-09-23 2012-09-21 疫苗疗法

Publications (1)

Publication Number Publication Date
CN104039346A true CN104039346A (zh) 2014-09-10

Family

ID=47018510

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201280057432.5A Pending CN104039346A (zh) 2011-09-23 2012-09-21 疫苗疗法
CN201910160828.6A Pending CN109847058A (zh) 2011-09-23 2012-09-21 疫苗疗法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201910160828.6A Pending CN109847058A (zh) 2011-09-23 2012-09-21 疫苗疗法

Country Status (23)

Country Link
US (1) US20240270829A1 (enExample)
EP (1) EP2758071B1 (enExample)
JP (1) JP6110861B2 (enExample)
KR (3) KR102129220B1 (enExample)
CN (2) CN104039346A (enExample)
AU (1) AU2012312126B2 (enExample)
BR (1) BR112014006871A2 (enExample)
CA (1) CA2811188C (enExample)
DK (1) DK2758071T3 (enExample)
EA (1) EA032494B1 (enExample)
ES (1) ES2712951T3 (enExample)
HU (1) HUE041277T2 (enExample)
IL (1) IL231564A0 (enExample)
MX (1) MX350928B (enExample)
MY (1) MY169574A (enExample)
PH (1) PH12014500657A1 (enExample)
PL (1) PL2758071T3 (enExample)
PT (1) PT2758071T (enExample)
SG (1) SG11201400795UA (enExample)
SI (1) SI2758071T1 (enExample)
TR (1) TR201901846T4 (enExample)
WO (1) WO2013044147A1 (enExample)
ZA (1) ZA201402071B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ630542A (en) 2012-08-16 2017-06-30 Ipierian Inc Methods of treating a tauopathy
US8980270B2 (en) 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
JP2017512751A (ja) 2014-02-14 2017-05-25 アイピエリアン，インコーポレイティド タウペプチド、抗タウ抗体、およびそれらの使用方法
CA3118692A1 (en) 2018-11-06 2020-05-14 Alsatech, Inc. Cell-based gene therapy for neurodegenerative diseases
SG11202112329RA (en) * 2019-05-21 2021-12-30 Ac Immune Sa Anti-abeta vaccine therapy
KR20250137159A (ko) 2023-01-26 2025-09-17 에이씨 이뮨 에스에이 항-a베타 백신 요법

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007068411A2 (en) * 2005-12-12 2007-06-21 Ac Immune S.A. Therapeutic vaccine
WO2010106127A2 (en) * 2009-03-18 2010-09-23 Ac Immune S.A. Method for therapeutic use

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9811401A (pt) 1997-08-28 2000-08-29 Ajay North America E Som Iodo Processos para proteger uma substância agrìcola contra pestes que são nocivas para a substância agrìcola e para a proteção de uma substãncia agrìcola, e, composição protetora para substâncias agrìcolas
AU2003292936A1 (en) 2002-12-24 2004-07-22 Neurochem (International) Limited Therapeutic formulations for the treatment of beta-amyloid related diseases
NZ567324A (en) * 2003-02-01 2009-08-28 Wyeth Corp Active immunization to generate antibodies to soluble A-beta
US8663650B2 (en) 2003-02-21 2014-03-04 Ac Immune Sa Methods and compositions comprising supramolecular constructs
JP4696079B2 (ja) * 2003-12-17 2011-06-08 ヤンセン アルツハイマー イミュノセラピー Ａβ免疫原性ペプチド担体結合物およびそれの製造方法
MX2007000998A (es) * 2004-07-30 2007-07-11 Rinat Neuroscience Corp Anticuerpos dirigidos peptido beta-amiloide y procedimientos que usan los mismos.
NZ581835A (en) * 2007-06-12 2012-09-28 Ac Immune Sa Monoclonal anti beta amyloid antibody

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007068411A2 (en) * 2005-12-12 2007-06-21 Ac Immune S.A. Therapeutic vaccine
WO2010106127A2 (en) * 2009-03-18 2010-09-23 Ac Immune S.A. Method for therapeutic use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
STOLTZNER S. E. ET AL.: "Temporal Accrual of Complement Proteins in Amyloid Plaques in Down’s Syndrome with Alzheimer’s Disease", 《AMERICAN JOURNAL OF PATHOLOGY》 *

Also Published As

Publication number Publication date
JP2014531455A (ja) 2014-11-27
KR20160005380A (ko) 2016-01-15
MX2014003325A (es) 2014-05-21
NZ622653A (en) 2015-12-24
HUE041277T2 (hu) 2019-05-28
KR20190035948A (ko) 2019-04-03
PT2758071T (pt) 2019-01-11
PL2758071T3 (pl) 2019-08-30
TR201901846T4 (tr) 2019-03-21
AU2012312126B2 (en) 2016-11-10
ES2712951T3 (es) 2019-05-16
AU2012312126A1 (en) 2014-03-27
EP2758071A1 (en) 2014-07-30
MX350928B (es) 2017-09-26
DK2758071T3 (en) 2019-02-18
WO2013044147A1 (en) 2013-03-28
IL231564A0 (en) 2014-04-30
CA2811188C (en) 2020-04-28
KR102129220B1 (ko) 2020-07-02
EA201400376A1 (ru) 2014-09-30
ZA201402071B (en) 2017-08-30
US20240270829A1 (en) 2024-08-15
EA032494B1 (ru) 2019-06-28
CA2811188A1 (en) 2013-03-23
JP6110861B2 (ja) 2017-04-05
SI2758071T1 (sl) 2019-01-31
EP2758071B1 (en) 2018-11-28
KR20160099732A (ko) 2016-08-22
MY169574A (en) 2019-04-22
BR112014006871A2 (pt) 2017-04-04
SG11201400795UA (en) 2014-10-30
PH12014500657A1 (en) 2014-05-05
CN109847058A (zh) 2019-06-07

Similar Documents

Publication Publication Date Title
US20240270829A1 (en) Vaccine Therapy
CN101330923B (zh) 治疗性疫苗
CN102428101B (zh) 用于治疗用途的方法
RU2551782C2 (ru) Специфические в отношении амилоида бета (а бета) 1-42 моноклональные антитела, обладающие терапевтическими свойствами
CN102946899B (zh) 药物组合物
JP2011251964A (ja) 超分子コンストラクトを含む方法および組成物
US20140314837A1 (en) Vaccine Therapy
NZ622653B2 (en) Vaccine therapy for the treatment of memory and/or cognitive impairments in subjects with down’s syndrome
HK1197732A (en) Vaccine therapy
HK1197732B (en) Vaccine therapy
JP4934433B2 (ja) 超分子コンストラクトを含む方法および組成物
JP2007527870A5 (enExample)
MX2008007149A (en) Therapeutic vaccine
HK1127486B (zh) 治疗性疫苗

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20140910